Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
出版年份 2013 全文链接
标题
Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
作者
关键词
-
出版物
OncoImmunology
Volume 2, Issue 2, Pages e23288
出版商
Informa UK Limited
发表日期
2013-01-29
DOI
10.4161/onci.23288
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dissection of T-cell Antigen Specificity in Human Melanoma
- (2012) R. S. Andersen et al. CANCER RESEARCH
- International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?
- (2012) Friederike Erdmann et al. INTERNATIONAL JOURNAL OF CANCER
- Myeloid-derived Suppressor Cells in Cancer Patients
- (2012) Alberto J. Montero et al. JOURNAL OF IMMUNOTHERAPY
- Cancer immunotherapy
- (2012) Thomas F. Gajewski Molecular Oncology
- Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
- (2012) Rikke Sick Andersen et al. Nature Protocols
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
- (2012) Pia Kvistborg et al. OncoImmunology
- A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
- (2011) S. Solito et al. BLOOD
- Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
- (2011) J. A. Kyte et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Regulatory T Cells
- (2010) Tatiana N. Golovina et al. CANCER JOURNAL
- Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma
- (2010) Steven E. Finkelstein et al. JOURNAL OF IMMUNOTHERAPY
- Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide
- (2010) C. Kim et al. ONCOLOGIST
- Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer
- (2009) Andrew J. Rech et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
- (2009) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- The safety of temozolomide in the treatment of malignancies
- (2009) Van Anh Trinh et al. Expert Opinion On Drug Safety
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers
- (2009) Sine Reker Hadrup et al. NATURE METHODS
- CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells
- (2008) M. Kleinewietfeld et al. BLOOD
- A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma
- (2008) Ahmad A. Tarhini et al. CANCER
- Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma
- (2008) Petra Rietschel et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient T cell depletion causes regression of melanoma metastases
- (2008) Mary Rasku et al. Journal of Translational Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now